AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02821637 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Eurofit Tests of Physical Fitness (Eurofit)
Description: Eurofit tests are a physical skills assessment. For the study, tests performed on the 1st and the 13th session of the program, then 3 more times : 2 months, 6 months and 12 months after the 13th weekly session.
Study NCT02821637 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Child Health Questionnaire (CHQ)
Description: The CHQ is a questionnaire about quality of life. The CHQ children form (CHQ-CF87) and the CHQ parent form (CHQ-PF50) are completed each time the Eurofit tests are performed : at the 1st and 13th weekly session then 2 months, 6 months and 12 months later.
Study NCT02821637 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Effort rehabilitation program
Description: Part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse, the program consists in 13 sessions of 1hour30 of adapted physical activity. The physical activity in this program use cycles of games where rules are adapted to the overweight or obese children. The activities are performed in a playful atmosphere, for example using creative games like tchoukball or peteca, with each session aiming a specific objective each time.
Study NCT00579592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H, rituximab, myfortic
Description: Campath-1H 30mg IV x 2 doses, rituximab 375mg/m2 IV x 1 dose, myfortic 720mg bid, cyclosporine po bid (target trough 200ng/ml) x 10-20 days
Study NCT04096742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin 0.05% lotion (Altreno)
Description: Altreno topical lotion
Study NCT04096742 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vehicle
Description: Lotion not containing active ingredient (tretinoin)
Study NCT00887406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 15mcg SD
Description: Single dose delivered via solution for nebulisation
Study NCT00887406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 3mcg SD
Description: single dose delivered via nebulsier
Study NCT01269775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teaching Methods
Description: We carried out a randomized controlled trial comparing three methods of teaching. These three instructional methods consist of face to face lecture, interactive internet based teaching and computer based teaching (lecture synchronized with presentation) regarding medical students' knowledge achievement and satisfaction.
Study NCT03709667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EX
Description: An individualized aerobic and resistance-exercise program will be developed for each participant on the basis of a maximal incremental exercise test and strength assessments performed at baseline. This test will measure aerobic capacity (VO2 max) and the metabolic or lactate threshold (VO2θ) (i.e., the level of O2 uptake that defines one's ability to perform prolonged work), using indirect calorimetry with an automated metabolic-measurement system. The intervention will comprise 24 sessions over 8 wk (3x/wk), supervised by a credentialed exercise specialist. Each session will consist of a 5-min warm-up, 30-40 min of aerobic activity on a treadmill, 15-20 min of resistance training, and a 5-min cool-down.
Study NCT03709667 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CON
Description: Participants attend 50-min sessions 3x/wk matched to EX for staff contact. A counselor will facilitate integrative group discussions, and will conduct a multimedia program addressing various health, wellness and lifestyle topics, such as nutrition, dental care, stress relief, sleep hygiene, relationships, immunizations, health screening, smoking, environmental health, and time management.
Study NCT00887406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 50mcg SD
Description: single dose delivered via solution for nebulisation
Study NCT00887406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SD
Description: single dose via nebuliser
Study NCT02735694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cycloserine
Description: Capsule containing 250 mg of Cycloserine
Study NCT02735694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cycloserine
Description: Capsule containing 250 mg of Cycloserine
Study NCT02735694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sugar capsule manufactured to mimic Cycloserine 250 mg capsule
Study NCT02735694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar capsule manufactured to mimic Cycloserine 250 mg capsule
Study NCT03589196 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ejaculation Preserving Photoselective Vaporization
Description: Ejaculation Preserving Photoselective Vaporization
Study NCT03589196 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ejaculation Preserving Plasma Kinetic Vaporization
Description: Ejaculation Preserving Plasma Kinetic Vaporization
Study NCT03589196 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ejaculation Preserving Transurethral Resection Of The Prostate
Description: Ejaculation Preserving Transurethral Resection Of The Prostate
Study NCT01030094 — intervention group
Intervention type: DRUG
Intervention: Topiramate
Description: This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
Study NCT01030094 — intervention group
Intervention type: DRUG
Intervention: Carbamazepine
Description: This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
Study NCT01030094 — intervention group
Intervention type: DRUG
Intervention: Valproic acid
Description: This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
Study NCT01030094 — intervention group
Intervention type: DRUG
Intervention: Normal control
Description: This is an observational study. Healthy female participants will be observed in Normal control group.
Study NCT00176930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)
Study NCT00176930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
Study NCT00176930 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: On Day -4, -3, -2, -1 total body irradiation is given twice daily.
Study NCT00176930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.
Study NCT00176930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Equine ATG (ATGAM)
Description: UCB recipients who have not had chemotherapy in the preceding 3 months will also receive Equine ATG (ATGAM) 15 mg/kg IV will be administered every 12 hours for 6 doses beginning on day -3 per institutional guidelines
Study NCT00448513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: catechin extracts
Description: comparison with placebo
Study NCT03409198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab blocks CTLA-4 and may deplete regulatory T cells
Study NCT03409198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab blocks PD-1 and thereby enhances the effector phase of the immune reaction, by enabling T cells to kill tumor cells and engage effectively with other PD-L1 expressing targets.
Study NCT03409198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: Chemotherapy
Study NCT03409198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Chemotherapy
Study NCT03409198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Chemotherapy
Study NCT00887406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 100mcg SD
Description: single dose delivered via solution for nebulisation
Study NCT00887406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 200mcg SD
Description: single dose via nebuliser
Study NCT00887406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 300mcg SD
Description: single dose via nebuliser
Study NCT00887406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 100mcg RD
Description: repeat dose via nebuliser
Study NCT00887406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 300mcg RD
Description: repeat dose vai nebuliser
Study NCT00887406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo RD
Description: repeat dose via nebuliser
Study NCT05169996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Food
Description: The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Food condition, the tangram pieces were tempting food products (i.e., pieces of chocolate). Players had to physically move the chocolate pieces with their hands and puzzle them together.
Study NCT05169996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Nonfood
Description: The game was played while sitting behind a table in the lab. The task in the game was to finish a tangram puzzle. In the Real Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of wood). Players had to physically move the wooden pieces with their hands and puzzle them together.
Study NCT05169996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality Food
Description: The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together.
Study NCT05169996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality Nonfood
Description: The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Nonfood condition, the tangram pieces were plain pieces (i.e., pieces of virtual wood). Players had to physically move the virtual wood pieces with the grab button on the controller and puzzle them together.
Study NCT03409198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy
Study NCT01817777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Small Pack
Description: A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
Study NCT01817777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Large Pack
Description: The large pack will consist of 1 month's supply of metformin.
Study NCT03524157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-087
Description: The intervention period consists of a therapy with PRO-087administered 4 times a day in the waking period for 10 days. with a security call to day 13.
Study NCT03524157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra
Description: The intervention period with active comparator drug consists of a therapy with systane administered 4 times a day in the waking period for 10 days. with a security call to day 13.
Study NCT05169996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality Food Branded
Description: The game was played by wearing a VR head-mounted display (HMD VR: HTC Vive) and people could interact in the virtual environment with the hand-held controllers. The task in the game was to finish a tangram puzzle. In the Virtual Reality Food condition, the tangram pieces were tempting food products (i.e., pieces of virtual chocolate). Players had to physically move the virtual chocolate pieces with the grab button on the controller and puzzle them together. In the background of the puzzle, a chocolate brand ('Milka') is shown
Study NCT02284542 — intervention group
Intervention type: PROCEDURE
Intervention: Awake
Description: Upon approximate lead positioning, the patient is brought to a conscious sedated state while maintaining local anesthetic. Stimulation of the spinal cord through the paddle lead is accomplished with an external pulse generator, while communicating with the patient regarding paresthesia coverage of painful regions.
Study NCT03524157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xyel Ofteno
Description: The intervention period with active comparator drug consists of a therapy with Xyel administered 4 times a day in the waking period for 10 days. with a security call to day 13.
Study NCT00160563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEVOCETIRIZINE
Description: 5mg/mL oral drops, 0.125 mg/kg body weight, bid for 18 months
Study NCT00160563 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral drops, bid for 18 months
Study NCT04109300 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HLADQA1*05A>G screening
Description: DNA will be extracted from whole blood collected from subjects in both arms using the MagNA Pure Compact instrument (Roche, Laval, Quebec, Canada). A custom TaqMan allelic discrimination assay (Applied Biosystems, Carlsbad, CA) will be used to determine the presence of wild-type and/or variant alleles in the class II HLA gene region at rs2097432 mapped to the HLA-DQA1\*05 region in infliximab-exposed IBD subjects. Genetic data will be used to determine whether or not one of methotrexate or azathioprine should be applied to the patient in the experimental arm.
Study NCT04109300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The treating physician will use clinical judgement to determine need for the addition of one of methotrexate or azathioprine to infliximab therapy.
Study NCT03070067 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
Study NCT01952977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Test breakfast
Study NCT01952977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test breakfast
Study NCT03526666 — intervention group
Intervention type: OTHER
Intervention: Peripheral blood collection
Description: Peripheral blood collection for the measurement of ascorbic acid levels and banking of plasma and buffy coat for future resrearch.
Study NCT00003451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Study NCT00003451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Study NCT01404247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).
Description: The OCT technician will attempt to image the eyes of neonates. The neonate may be given Cyclomydril ophthalmic solution, if needed for dilation. Cyclomydril dosing for this study is 1 drop every 5 minutes times 2.
Study NCT01404247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT imaging.
Description: All newborns meeting eligibility requirements will undergo spectral domain optical coherence tomography imaging in order to better characterize the retina and optic nerve in newborns
Study NCT03058887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention - Cycling
Description: The patients that will be randomly allocated to the exercise group - cycling will be requested to perform an exercise session on a cycle ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
Study NCT03058887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention - arm cranking
Description: The patients that will be randomly allocated to the exercise group - arm cranking will be requested to perform an exercise session on an arm crank ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
Study NCT03208790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella sativa buccal tablets 10mg
Description: thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 10mg
Study NCT03208790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella sativa buccal tablets 5mg
Description: thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 5mg
Study NCT03208790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo buccal tablets
Description: capsules with the same color and form as the active ones but without active ingredient will be given to the patients
Study NCT03215160 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: mobilization exercises (Patellofemoral joint, Tibiofemoral joint, Soft tissue) and classical exercises performed in the early post-op period
Study NCT03215160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises
Description: mobilization exercises (Patellofemoral joint, Tibiofemoral joint, Soft tissue) and classical exercises performed in the early post-op period
Study NCT04709523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bovine-derived xenograft with i-PRF
Description: Bovine-derived xenograft was mixed with i-PRF and was placed in the augmentation site.
Study NCT04709523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bovine-derived xenograft alone
Description: Bovine-derived xenograft was placed in the augmentation site.
Study NCT02284542 — intervention group
Intervention type: PROCEDURE
Intervention: Non-Awake
Description: The patient is maintained under general anesthesia for the full duration of the implant. Upon approximate lead positioning, bilateral EMG of myotomes overlapping dermatomal regions of pain are monitored. Stimulation is delivered through the lead by an external pulse generator in order to elicit compound muscle action potentials (CMAPs) in the target regions. Lead placement is targeted to have symmetric CMAPs (i.e. physiologic midline) and adequate coverage of the painful regions as described by Falowski et al.~(Falowski et al., 2011).
Study NCT03996759 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory diagnostic medicine
Description: Metabolomic profiling and laboratory diagnosis including blood routine examination, liver function, renal function, myocardial enzyme, coagulation, arterial blood gas analysis, C-reactive protein, procalcitonin, B-type natriuretic peptide, myoglobin, lipopolysaccharide, cytokines (TNF-α, IL-1β, IL-6, etc.), immune cell markers (CD3+, CD4+, CD8+, etc.), and stool routine as well as intestinal microecology analysis.
Study NCT05346497 — intervention group
Intervention type: PROCEDURE
Intervention: Bentall
Description: Bentall procedure: include replacement of both aortic valve and root
Study NCT05346497 — intervention group
Intervention type: PROCEDURE
Intervention: David
Description: David procedure: include replacement of aortic root and aortic valvuloplasty
Study NCT05346497 — intervention group
Intervention type: PROCEDURE
Intervention: ARR
Description: Aortic root reconstruction: reconstruction instead of replacement of aortic root, without surgery of the valve. include sandwich procedure, adventitia invertion procedure, etc.
Study NCT03468829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171 Dose 1
Description: Oral inhalation of ALX-0171 Dose 1 once daily for a maximum of 14 days
Study NCT03468829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171 Dose 2
Description: Oral inhalation of ALX-0171 Dose 2 once daily for a maximum of 14 days
Study NCT03468829 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral inhalation of Placebo once daily for a maximum of 14 days